Clinical implications of amylin and amylin deficiency. - sprookjes - yvandenbroek - TriplyDB

Clinical implications of amylin and amylin deficiency.

Clinical implications of amylin and amylin deficiency.

http://www.wikidata.org/entity/Q33757375

about

Regulation of amylin release from cultured rabbit gastric fundic mucosal cells Apoptosis in pancreatic β-islet cells in Type 2 diabetes In silico design of optimal ratio for co-administration of pramlintide and insulin in type 1 diabetes.Chemical modification of class II G protein-coupled receptor ligands: frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies Disordered eating behavior in individuals with diabetes: importance of context, evaluation, and classification Rationally designed, nontoxic, nonamyloidogenic analogues of human islet amyloid polypeptide with improved solubility Structural similarities and differences between amyloidogenic and non-amyloidogenic islet amyloid polypeptide (IAPP) sequences and implications for the dual physiological and pathological activities of these peptides.Islet amyloid polypeptide in pancreatic islets from type 1 diabetic subjects.Pramlintide for the treatment of diabetes mellitus.Vascular actions of calcitonin gene-related peptide and adrenomedullin.Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes.Islet amyloid polypeptide in pancreatic islets from type 2 diabetic subjects.Update in the pharmacologic treatment of diabetes mellitus: focus on pramlintide and exenatide.Adjunctive therapy with pramlintide in patients with type 1 or type 2 diabetes mellitus.Role of Amylin in Type 1 and Type 2 Diabetes.Hyperamylinemia Increases IL-1β Synthesis in the Heart via Peroxidative Sarcolemmal Injury Amylin uncovered: a review on the polypeptide responsible for type II diabetes.Through the looking glass: current and future perspectives on the role of hormonal interplay in glucose homeostasis.Novel insights into amylin aggregation.A model of glucose-insulin-pramlintide pharmacokinetics and pharmacodynamics in type I diabetes.Optimizing diabetes treatment using an amylin analogue.Amylin replacement therapy in patients with type 1 diabetes.The physiology of amylin and insulin: maintaining the balance between glucose secretion and glucose uptake.Computational insights into the inhibition and destabilization of morin on the oligomer of full-length human islet amyloid polypeptide.

P2860

Q24807005-9A5513D5-DF7F-46AB-BD65-F5B1D5695A26 Q26747141-7438AE89-B173-4072-A92B-743A2ED94D1D Q30410405-A5CA1358-5A70-4EB9-BED4-63739C2F97A1 Q33624771-818930B2-4726-450B-BBF3-D082AD52D244 Q33683839-B22FC322-BD95-4365-BC3F-EC2B69FCD680 Q34230460-B4DD1254-921F-4B8A-B603-3B92BBD43BFE Q34979345-FB1A3AEC-F182-4BC0-ADE6-3A7A7E924F7E Q35159109-DB321223-CCC3-464D-874D-31C364BC1E26 Q35169449-ECC66DA3-1E5A-40BF-9F4C-D2BC0CE29498 Q35842993-FC15E81D-48AE-4429-8D82-3503FCB4C10F Q36012965-836AF75F-0773-460A-AF15-7444D2915E8F Q36235348-624473FD-4FBD-45B5-A328-ECA7A4E093DF Q36593147-B453D7A6-00B5-440E-AC52-4B149E1CAD4A Q36634230-ABBB8FF3-61B6-4805-99F5-A574F152F917 Q38596374-41AD71FE-6E58-4595-AC69-E51979BF97C1 Q39661461-C80C3C50-A9CF-4657-B214-26D7A64E0F52 Q39846208-A6131D62-FBFA-48CA-8360-7C04CA6F48A5 Q40215795-D4F7A9A3-2EA5-4676-B247-AF4494DE2373 Q40741890-8B67FB71-A403-4BB8-9430-2D5125438D08 Q42723586-913A88DF-A54B-4E39-A82D-5AA4A9CF08C1 Q44989550-4989E599-6CF1-4C24-9CE9-3031E35CEDB5 Q46047804-852961F5-20D0-4545-8A38-C153E08CB07E Q51497020-80690E48-F8C5-4A49-B9A5-60DD54E1507B Q53313558-7E6855DA-6540-4B6C-B563-7D834D076028

P2860

Clinical implications of amylin and amylin deficiency.

http://www.wikidata.org/entity/Q33757375

description

1999 nî lūn-bûn

@nan

1999 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

1999 թվականի մայիսին հրատարակված գիտական հոդված

@hy

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

name

Clinical implications of amylin and amylin deficiency.

@ast

Clinical implications of amylin and amylin deficiency.

@en

type

label

Clinical implications of amylin and amylin deficiency.

@ast

Clinical implications of amylin and amylin deficiency.

@en

prefLabel

Clinical implications of amylin and amylin deficiency.

@ast

Clinical implications of amylin and amylin deficiency.

@en

P1433

Q33757375-8F1344C6-8D58-4262-9769-1E7A5D32B4CE

P1476

Q33757375-F4708C34-1137-439E-AB99-AD48F49195C1

P2093

Q33757375-1BF5DCF9-8520-4126-A34C-468011B53F88

Q33757375-CA995A03-8678-498A-82F2-FA32A4A4F163

Q33757375-CDDBC05D-A585-4809-A97F-E36F6F22715D

P2860

Q33757375-0B21419C-9663-41F2-BA4E-13740F129ED2

Q33757375-0C0AEBA3-40DB-4DE8-8377-B21FE7480B96

Q33757375-0E45F4A5-DEFE-4A2F-9029-5B7D1E325D31

Q33757375-3EC944E8-C56B-4ABB-9303-CAA96FB61D3D

Q33757375-60B853BF-6202-4C6E-9FD6-FA63AC2F3E95

Q33757375-62D228A7-5C25-4A7C-8F6E-88994D947258

Q33757375-6E1BD3A1-C109-47A9-8EC3-0DF74ACD8541

Q33757375-7A621516-9565-4A65-9B96-9C01FBE63990

Q33757375-83218029-055F-42FD-A74F-4C6666B77ADA

Q33757375-88768EE1-008E-44C6-A3E4-642F35CBA65C

P304

Q33757375-22E662AE-928A-4BB5-9DF4-F4B3F963BBF9

P31

Q33757375-DB00F44D-C477-4A67-844A-E4F3E2769667

P356

Q33757375-10737B99-ACFF-42E6-B149-44984D07654D

P433

Q33757375-C2498CC7-EECD-4D96-92A0-A244714BF0A8

P478

Q33757375-5ABA44C7-B8B3-4497-90A4-2A2E088E0E86

P577

Q33757375-5D943932-3EFE-432C-AD92-D1B56656AE0A

P698

Q33757375-9ED1960C-17B3-4387-9EFE-A103BBEFE152

P356

014572179902500310

P1433

The Diabetes Educator

P1476

Clinical implications of amylin and amylin deficiency.

@en

P2093

D F Kruger

http://www.w3.org/2001/XMLSchema#string

P M Gatcomb

http://www.w3.org/2001/XMLSchema#string

S K Owen

http://www.w3.org/2001/XMLSchema#string

P2860

Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

Impaired net hepatic glycogen synthesis in insulin-dependent diabetic subjects during mixed meal ingestion. A 13C nuclear magnetic resonance spectroscopy study.

Highly variable gastric emptying in patients with insulin dependent diabetes mellitus.

Co-secretion of amylin and insulin from cultured islet beta-cells: modulation by nutrient secretagogues, islet hormones and hypoglycemic agents.

Postprandial hyperglycemia in patients with noninsulin-dependent diabetes mellitus. Role of hepatic and extrahepatic tissues

Abnormal meal carbohydrate disposition in insulin-dependent diabetes. Relative contributions of endogenous glucose production and initial splanchnic uptake and effect of intensive insulin therapy

Natural history of beta-cell dysfunction in NIDDM.

Effects of 4 weeks' administration of pramlintide, a human amylin analogue, on glycaemia control in patients with IDDM: effects on plasma glucose profiles and serum fructosamine concentrations.

Structure and biology of amylin.

P304

389-97; quiz 398

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/014572179902500310

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

1999-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

10531859

http://www.w3.org/2001/XMLSchema#string